Abstract: Provided herein are pharmaceutical compositions and methods for providing blood plasma concentrations of ensifentrine to specific patient group populations including those with modified renal or hepatic impairment.

Abstract: Provided herein are pharmaceutical compositions and methods for treating COPD or COPD exacerbations in subjects suffering from, for example, moderate COPD, or subjects with decreased eosinophil concentrations, or are suffering from chronic bronchitis. Also provided herein are methods of increasing trough lung function in subjects suffering from moderate COPD.

Abstract: The invention relates to a liquid pharmaceutical composition comprising a dose of a compound which is ensifentrine or a pharmaceutically acceptable salt thereof, wherein the liquid pharmaceutical composition provides a blood plasma concentration of ensifentrine after administration by inhalation to a human subject having COPD, which blood plasma concentration of ensifentrine has: a mean Cmax Of from about 400 pg/mL to about 720 pg/mL; and/or a mean AUC0-tau of from about 2000 pg/mL*h to about 3000 pg/mL*h; and/or a mean Tmax at from about 0.6 hours to about 1.5 hours. The invention also provides a method of treating COPD.

Abstract: The invention relates to a liquid pharmaceutical composition comprising a dose of a compound which is ensifentrine or a pharmaceutically acceptable salt thereof, wherein the liquid pharmaceutical composition provides a blood plasma concentration of ensifentrine after administration by inhalation to a human subject having COPD, which blood plasma concentration of ensifentrine has: a mean Cmax of from about 400 pg/mL to about 720 pg/mL; and/or a mean AUC0-tau of from about 2000 pg/mL*h to about 3000 pg/mL*h; and/or a mean Tmax at from about 0.6 hours to about 1.5 hours. The invention also provides a method of treating COPD.